Table 1 Demographic and clinical features of patients managed with prolonged intravenous colistin for infections caused by multidrug-resistant Gram-negative bacteria.
From: Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Characteristics of patients | Median (range) n (%) |
|---|---|
Demographic | |
Age, years [median (range)] | 51 (18 – 79) |
Sex, male | 12/17 (70%) |
APACHE II score | |
On admission to ICU [median (range)] | 14 (7 – 35) |
On 1st day of colistin treatment [median (range)] | 14 (6 – 22) |
Comorbidity | |
Malignancy | 2/17 (11%) |
Hemodialysis | 2/17 (11%) |
Urogenital disorders | 3/17 (18%) |
Heart dysfunction | 5/17 (29%) |
Diabetes mellitus | 5/17 (29%) |
Lung dysfunction | 5/17 (29%) |
Liver failure | 1/17 (6%) |
Hematological disorders | 3/17 (18%) |
Neurological disorders | 8/17 (47%) |
Neuropathy/myopathy | 4/17 (23%) |
Trauma | 7/17 (41%) |
Transfusion | 15/17 (88%) |
Prior hospitalization | 12/17 (70%) |
Prior surgery | 14/17 (82%) |
Elective | 9/14 (64%) |
Emergency | 5/14 (36%) |
Prosthetic material | 11/17 (64%) |
Catheters/Invasive devices | |
Tracheostomy | 14/17 (82%) |
CSF drainage | 5/17 (29%) |
Prior medications | |
Prior antibiotic use | 17/17 (100%) |
Prior antifungal use | 8/17 (47%) |
Anti-tumor treatment | 0/17 (0%) |
Cortisone treatment | 9/17 (53%) |
Duration of hospitalization (days) [median (range)] | 152 (29 – 591) |
Duration of stay in ICU (days) [median (range)] | 70 (22 – 134) |
Site of infection* | |
Pneumonia | 13/19 (68%) |
Bacteremia | 1/19 (5%) |
Urinary tract infection | 2/19 (11%) |
Meningitis | 2/19 (11%) |
Surgical site infection | 1/19 (5%) |
Pathogens† | |
Pseudomonas aeruginosa | 12/20 (60%) |
Acinetobacter baumannii | 5/20 (25%) |
Klebsiella pneumoniae | 2/20 (10%) |
Enterobacter cloacae | 1/20 (5%) |
Mortality | 7/17 (41%) |